Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents

Biochemical and Biophysical Research Communications

Volumn 431, Issue 3, 2013, Pages 623-629

  Chen, Gang ^a,b   Kronenberger, Peter ^a,c   Teugels, Erik ^a   Umelo, Ijeoma Adaku ^a   De Grève, Jacques ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^b GUANGXI MEDICAL UNIVERSITY   (China)

^c Erasmushogeschool Brussel   (Belgium)

Author keywords

Afatinib; Cetuximab; EGFR; Non small cell lung cancer; RNA interference; T790M

Indexed keywords

AFATINIB; CASPASE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; MESSENGER RNA; PROTEIN TYROSINE KINASE INHIBITOR; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL GROWTH; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE TARGETING; HUMANS; LUNG NEOPLASMS; MUTATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, SMALL INTERFERING;

EID: 84873729228     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.12.070     Document Type: Article

References (21)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
2. Bell D.W., Lynch T.J., Haserlat S.M., Harris P.L., Okimoto R.A., Brannigan B.W., Sgroi D.C., Muir B., Riemenschneider M.J., Iacona R.B., Krebs A.D., Johnson D.H., Giaccone G., Herbst R.S., Manegold C., Fukuoka M., Kris M.G., Baselga J., Ochs J.S., Haber D.A. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J. Clin. Oncol. 2005, 23:8081-8092.
3. Sordella R., Bell D.W., Haber D.A., Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004, 305:1163-1167.
4. Engelman J.A., Mukohara T., Zejnullahu K., Lifshits E., Borras A.M., Gale C.M., Naumov G.N., Yeap B.Y., Jarrell E., Sun J., Tracy S., Zhao X., Heymach J.V., Johnson B.E., Cantley L.C., Janne P.A. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J. Clin. Invest. 2006, 116:2695-2706.
5. Yun C.H., Mengwasser K.E., Toms A.V., Woo M.S., Greulich H., Wong K.K., Meyerson M., Eck M.J. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc. Natl. Acad. Sci. USA 2008, 105:2070-2075.
6. Kim Y., Ko J., Cui Z., Abolhoda A., Ahn J.S., Ou S.H., Ahn M.J., Park K. The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor. Mol. Cancer Ther. 2012, 11:784-791.
7. Yang J.C.-H., Schuler M.H., Yamamoto N., O'Byrne K.J., Hirsh V., Mok T., Geater S.L., Orlov S.V., Tsai C.-M., Boyer M.J., Su W.-C., Bennouna J., Kato T., Gorbunova V., Lee K.H., Shah R.N.H., Massey D., Lorence R.M., Shahidi M., Sequist L.V. LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. J. Clin. Oncol. 2012, 30(Suppl.). abstr LBA7500.
8. Rothenberg S.M., Engelman J.A., Le S., Riese D.J., Haber D.A., Settleman J. Modeling oncogene addiction using RNA interference. Proc. Natl. Acad. Sci. USA 2008, 105:12480-12484.
9. Tang Z., Du R., Jiang S., Wu C., Barkauskas D.S., Richey J., Molter J., Lam M., Flask C., Gerson S., Dowlati A., Liu L., Lee Z., Halmos B., Wang Y., Kern J.A., Ma P.C. Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. Br. J. Cancer 2008, 99:911-922.
10. Yamanaka S., Gu Z., Sato M., Fujisaki R., Inomata K., Sakurada A., Inoue A., Nukiwa T., Kondo T., Horii A. SiRNA targeting against EGFR, a promising candidate for a novel therapeutic application to lung adenocarcinoma. Pathobiology 2008, 75:2-8.
11. Reynolds A., Leake D., Boese Q., Scaringe S., Marshall W.S., Khvorova A. Rational siRNA design for RNA interference. Nat. Biotechnol. 2004, 22:326-330.
12. Ui-Tei K., Naito Y., Takahashi F., Haraguchi T., Ohki-Hamazaki H., Juni A., Ueda R., Saigo K. Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference. Nucleic Acids Res. 2004, 32:936-948.
13. Jagla B., Aulner N., Kelly P.D., Song D., Volchuk A., Zatorski A., Shum D., Mayer T., De Angelis D.A., Ouerfelli O., Rutishauser U., Rothman J.E. Sequence characteristics of functional siRNAs. RNA 2005, 11:864-872.
14. Chen G., Kronenberger P., Teugels E., Umelo I.Adaku, De Greve J. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. BMC Med. 2012, 10:28.
15. Chen G., Kronenberger P., Umelo I.A., Teugels E., De Grève J. Quantification of epidermal growth factor receptor T790M mutant transcripts in lung cancer cells by real-time reverse transcriptase-quantitative polymerase chain reaction. Anal. Biochem. 2010, 398:266-268.
16. Chen G., Kronenberger P., Teugels E., De Grève J. Influence of RT-qPCR primer position on EGFR interference efficacy in lung cancer cells. Biol. Proced. Online 2011, 13:1.
17. Koivusalo R., Krausz E., Helenius H., Hietanen S. Chemotherapy compounds in cervical cancer cells primed by reconstitution of p53 function after short interfering RNA-mediated degradation of human papillomavirus 18 E6 mRNA: opposite effect of siRNA in combination with different drugs. Mol. Pharmacol. 2005, 68:372-382.
18. Chou T.C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 2006, 58:621-681.
19. Regales L., Gong Y., Shen R., de Stanchina E., Vivanco I., Goel A., Koutcher J.A., Spassova M., Ouerfelli O., Mellinghoff I.K., Zakowski M.F., Politi K.A., Pao W. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J. Clin. Invest. 2009, 119:3000-3010.
20. Janjigian Y.Y., Groen H.J., Horn L., Smit E.F., Fu Y., Wang F., Shahidi M., Denis L.J., Pao W., Miller V.A. Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib. J. Clin. Oncol. 2011, (Suppl.). Abstract No:7525^.
21. Roda J.M., Joshi T., Butchar J.P., McAlees J.W., Lehman A., Tridandapani S., Carson W.E. The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines. Clin. Cancer Res. 2007, 13:6419-6428.